Original Article

You have full text access to this OnlineOpen article

Phase II study of alemtuzumab in chronic lymphoproliferative disorders

  1. Alessandra Ferrajoli M.D.1,†,*,
  2. Susan M. O'Brien M.D.1,
  3. Jorge E. Cortes M.D.1,
  4. Francis J. Giles M.D.1,
  5. Deborah A. Thomas M.D.1,
  6. Stefan Faderl M.D.1,
  7. Razelle Kurzrock M.D.2,
  8. Susan Lerner M.S.1,
  9. Dimitrios P. Kontoyiannis M.D.3,
  10. Michael J. Keating M.B., B.S.1

Article first published online: 26 JUN 2003

DOI: 10.1002/cncr.11551

Issue

Cancer

Cancer

Volume 98, Issue 4, pages 773–778, 15 August 2003

Additional Information

How to Cite

Ferrajoli, A., O'Brien, S. M., Cortes, J. E., Giles, F. J., Thomas, D. A., Faderl, S., Kurzrock, R., Lerner, S., Kontoyiannis, D. P. and Keating, M. J. (2003), Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer, 98: 773–778. doi: 10.1002/cncr.11551

Author Information

  1. 1

    Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  2. 2

    Department of Bioimmunotherapy, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  3. 3

    Department of Infectious Diseases, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  1. †

    Fax: (713) 794-4297

*Department of Leukemia/Unit 428, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030

Publication History

  1. Issue published online: 1 AUG 2003
  2. Article first published online: 26 JUN 2003
  3. Manuscript Accepted: 27 APR 2003
  4. Manuscript Revised: 10 APR 2003
  5. Manuscript Received: 24 FEB 2003

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (82K)

REFERENCES

  • 1
    Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature. 1988; 332: 323–327.
  • 2
    Hale G, Xia MQ, Tighe HP, Dyer MJ, Waldmann H. The CAMPATH-1 antigen (CDw52). Tissue Antigens. 1990; 35: 118–127.
    Direct Link:
  • 3
    Rowan W, Tite J, Topley P, Brett SJ. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology. 1998; 95: 427–436.
    Direct Link:
  • 4
    Ginaldi L, De Martinis M, Matutes E, et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res. 1998; 22: 185–191.
  • 5
    Keating MJ, O'Brien S, Kontoyiannis D, et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leukemia Lymphoma. 2002; 43: 1755–1762.
  • 6
    Hale G, Dyer MJ, Clark MR, et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet. 1988; 2: 1394–1399.
  • 7
    Lim SH, Davey G, Marcus R. Differential response in a patient treated with Campath-1H monoclonal antibody for refractory non-Hodgkin lymphoma. Lancet. 1993; 341: 432–433.
  • 8
    Flynn JM, Byrd JC. Campath-1H monoclonal antibody therapy. Curr Opin Oncol. 2000; 12: 574–581.
  • 9
    Osterborg A, Fassas AS, Anagnostopoulos A, Dyer MJ, Catovsky D, Mellstedt H. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol. 1996; 93: 151–153.
    Direct Link:
  • 10
    Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H treatment in chronic lymphocytic leukemia. J Clin Oncol. 1997; 15: 1567–1574.
  • 11
    Pawson R, Dyer MJ, Barge R, et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol. 1997; 15: 2667–2672.
  • 12
    Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996; 87: 4990–4997.
  • 13
    Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999; 17: 1244.
  • 14
    Lesprit P, Scieux C, Lemann M, Carbonelle E, Modai J, Molina JM. Use of the cytomegalovirus (CMV) antigenemia assay for the rapid diagnosis of primary CMV infection in hospitalized adults. Clin Infect Dis. 1998; 26: 646–650.
  • 15
    Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002; 99: 3554–3561.
  • 16
    Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol. 2002; 20: 3891–3897.
  • 17
    Dearden CE, Matutes E, Cazin B, et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001; 98: 1721–1726.
  • 18
    Keating MJ, Cazin B, Coutre S, et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol. 2002; 20: 205–213.
  • 19
    Lundin J, Osterborg A, Brittinger G, et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H treatment in low-grade non-Hodgkin's lymphoma. J Clin Oncol. 1998; 16: 3257–3263.
  • 20
    Lundin J, Hagberg H, Repp R, et al. Phase II study of alemtuzumab (anti-CD52 monoclonal antibody, Campath-1H) in patients with advanced mycosis fungoides/Sezary syndrome. Blood. 2003; 101: 4267–4272.
  • 21
    Nguyen DD, Cao TM, Dugan K, Starcher SA, Fechter RL, Coutre SE. Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Clin Lymphoma. 2002; 3: 105–110.
  • 22
    Perkins JG, Flynn JM, Howard RS, Byrd JC. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer. 2002; 94: 2033–2039.
    Direct Link:
  • 23
    Faderl S, Thomas DA, O'Brien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood. 2003; 101: 3413–3415.
View Full Article (HTML) Get PDF (82K)